|CNAT -- USA Stock|| |
USD 4.49 0.16 3.44%
Independent Chairman of the Board
Mr. David F. Hale is the Independent Chairman of the Board of Conatus Pharmaceuticals Inc. Since May 2006, he has served as Chairman CEO of Hale BioPharma Ventures. He was previously President and CEO of CancerVax Corporationrationration which merged with Micromet, Inc from October 2000 through May 2006, when he became Chairman of the combined companies. He is a serial entrepreneur who was involved in the founding andor development of a number of biotechnology and specialty pharmaceutical companies. After joining Hybritech, Inc., in 1982, he was President Chief Operating Officer and became CEO in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a cofounder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000. Prior to joining Hybritech, he was Vice President and General Manager of BBL Microbiology Systems and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporationrationration, a division of Johnson Johnson, Inc. Mr. Hale is Chairman of Santarus, Inc and previously served as Chairman of Somaxon, Inc. prior to its acquisition in 2013. He also serves as Chairman of Colorescience, Inc., Ridge Diagnostics, Crisi, Inc., Intrepid Therapeutics, Neurelis, Inc., Agility Clinical, Advantar Laboratories, Inc. and Katama Pharmaceuticals, Inc. He also is a cofounder and serves on the Board of Directors of BIOCOM, is a former member of the Board of the Biotechnology Industry Organization, and the Biotechnology Institute. He also serves on the Board of Directors of the San Diego Economic Development Corporationrationration, and as Chairman of the Board of Trustees of Rady Childrens Hospital of San Diego. He is a cofounder of the CONNECT Program in Technology and Entrepreneurship
Age: 66 Chairman Since 2012
Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.